Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy
    Meeting Abstract

    Cercek, A.; Dos Santos Fernandes, G.; Roxburgh, C.; Ng, S.; Yaeger, R.; Segal, N.; Ganesh, K.; Reidy, D.; Smith, J. J.; Nash, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
    Journal Article

    Kumar, A.; Vardhana, S.; Moskowitz, A. J.; Porcu, P.; Dogan, A.; Dubovsky, J. A.; Matasar, M. J.; Zhang, Z.; Younes, A.; Horwitz, S. M.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Targeting phosphatidylserine enhances the anti-tumor response to radiation therapy and immune checkpoint blockade in a preclinical melanoma model
    Meeting Abstract

    Budhu, S.; Giese, R.; Gupta, A.; Schad, S.; De Henau, O.; Zappasodi, R.; Campesato, L.; Barker, C.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab
    Meeting Abstract

    Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Whole genome sequencing of extramedullary myeloma autopsy tumors reveals a genomic portrait at culmination of clonal convergence
    Meeting Abstract

    Yellapantula, V. D.; Rustad, E. H.; Glozdik, D.; Gundem, G.; Fan, J.; Medina, J.; Patel, A.; Patel, M.; Hultcrantz, M.; Peled, J. U.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Drugging the human microbiome for combination with tumor immunotherapy
    Meeting Abstract

    Cook, D. N.; Peled, J.; van den Brink, M.; Jayaraman, L.
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • Role of single agent and combination chemotherapy strategies in relapsed/refractory peripheral T-cell lymphoma: Results from the complete registry
    Meeting Abstract

    Stuver, R.; Khan, N.; Schwartz, M.; Acosta, M.; Federico, M.; Gisselbrecht, C.; Lansigan, F.; Pinter-Brown, L. C.; Pro, B.; Shustov, A. R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Chaffee, K. G.; Furman, R. R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Continuous mobile wearable bio-monitoring of newly diagnosed multiple myeloma patients undergoing initial chemotherapy
    Meeting Abstract

    Tavitian, E.; Mastey, D.; Salcedo, M.; Zarski, A.; Chansakul, A.; Diab, V.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; more...
    Blood (2018)

    Fulltext@MSK | Save